Branded

GSK taps EMD Serono’s Martinez-Davis as U.S. pharmaceuticals president
Maya Martinez-Davis will assume the role as GSK president of U.S. pharmaceuticals, succeeding Jack Bailey, who will remain as a strategic consultant to GSK through 2020.
Daiichi Sankyo gets FDA nod for Turalio
Daiichi Sankyo’s Turalio is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery, the company said.

FDA approves new indication for Merck’s Keytruda

Keytruda is now the first anti-PD-1 therapy approved for the treatment of previously treated patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1.
Mylan, Pfizer’s Upjohn to merge, form new company

Pfizer is set to combine its off-patent and generics business with Mylan in an all-stock deal that will create a new company led by executives from both companies.
Upsher-Smith acquires Dr. Reddy's neurology-branded products

Upsher-Smith has completed its acquisition of Dr. Reddy's Tosymra and Zembrace SymTouch.
Karyopharm Therapeutics gets FDA OK for Xpovio

Karyopharm Therapeutics' Xpovio provides a treatment option for patients with multiple myeloma that has no available therapy.
Upsher-Smith to commercialize Klor-Con and potassium chloride products

Upsher-Smith Laboratories will commercialize and continue to manufacture Klor-Con (potassium chloride) and potassium chloride product families.
Sandoz offers free Symjepi to Americares for low-income and uninsured patients

Sandoz has donated more than 4,000 packs (more than 8,000 individual injections) of its Symjepi (epinephrine 0.3 mg) injectable medication to Americares for free distribution.
Ocular Therapeutix launches Dextenza

Dextenza now is approved for the treatment of both ocular inflammation and pain following ophthalmic surgery.
Allergan's Botox gets FDA approval for new indication

Allergan's Botox is the first neurotoxin treatment approved for pediatric patients ages 2-to-17 years old with upper limb spasticity.

GSK taps EMD Serono’s Martinez-Davis as U.S. pharmaceuticals president

Daiichi Sankyo gets FDA nod for Turalio

FDA approves new indication for Merck’s Keytruda

Mylan, Pfizer’s Upjohn to merge, form new company

Upsher-Smith acquires Dr. Reddy's neurology-branded products

Karyopharm Therapeutics gets FDA OK for Xpovio

Upsher-Smith to commercialize Klor-Con and potassium chloride products

Sandoz offers free Symjepi to Americares for low-income and uninsured patients

Ocular Therapeutix launches Dextenza

Allergan's Botox gets FDA approval for new indication